Company news
Atea Pharmaceuticals, Inc. news in 2021
Atea Pharmaceuticals, Inc.'s news releases, calls and decks from 2021, newest first.
Atea Pharmaceuticals Introduces New Strategic Clinical Development Program for AT-527 in COVID-19
December 13, 2021
Atea Pharmaceuticals Provides Update on Strategic Collaboration with Roche
November 15, 2021
Atea Pharmaceuticals Provides Clinical and Corporate Update and Reports Third Quarter 2021 Financial Results
November 10, 2021
Atea Pharmaceuticals to Host Third Quarter Financial Results Conference Call on November 11, 2021
November 3, 2021
Atea Pharmaceuticals Provides Update and Topline Results for Phase 2 MOONSONG Trial Evaluating AT-527 in the Outpatient Setting
October 18, 2021
Atea Pharmaceuticals Announces Publication of Data Highlighting AT-752’s Potent In Vitro and In Vivo Activity Against Dengue and Other Flaviviruses
August 23, 2021
Atea Pharmaceuticals Provides Clinical and Corporate Update and Reports Second Quarter 2021 Financial Results
August 11, 2021
Atea Pharmaceuticals Announces Achievement of AT-527 Development Milestone Under License Agreement with Roche
June 15, 2021
Atea Pharmaceuticals Appoints Claudio Avila, MB, BS, Ph.D., as Senior Vice President of Medical Affairs
June 14, 2021
Atea Pharmaceuticals Appoints Jerome Adams, M.D., M.P.H., to Board of Directors
May 19, 2021
Atea Pharmaceuticals Reports First Quarter 2021 Financial Results and Provides Corporate Update
May 12, 2021
Atea Pharmaceuticals Announces First Patient Dosed in Global Phase 3 MORNINGSKY Trial of AT-527 for Treatment of COVID-19
April 28, 2021
Atea Pharmaceuticals Reports Full Year 2020 Financial Results and Provides Corporate Update
March 29, 2021
Atea Pharmaceuticals Presents Favorable Phase 1 Results for AT-527 at 28th Annual Conference on Retroviruses and Opportunistic Infections
March 5, 2021
Atea Pharmaceuticals Announces Chugai In-License of AT-527 from Roche for the Treatment of COVID-19 in Japan
February 18, 2021
Atea Pharmaceuticals Announces Publication of Preclinical Data Highlighting Potent Activity of AT-527 Against SARS-CoV-2
February 7, 2021
Atea Pharmaceuticals Announces First Patient Dosed in Phase 2 Virology Trial of AT-527 in Outpatient Setting
February 3, 2021
Atea Pharmaceuticals Expands Senior Management Team with Key Additions in Regulatory Affairs and Investor Relations and Corporate Communications
January 18, 2021
Calls in 2021
Decks in 2021
- Q1 2021 Earnings Presentation
Earnings · 17 slides · May 13, 2021